Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Lifestyle diseases such as high cholesterol, liver disorders, diabetes, and other metabolic conditions are rising rapidly across the world. Swami Ramdev explains how yoga, pranayama, disciplined ...

"Monogenic" diseases, triggered by mutations in just one gene, may actually be more complex than scientists thought.

When appointments are available within a short timeframe, individuals are more likely to address concerns early”— Chad ...

Researchers at Graz University of Technology are using virtual reality and large language models to support people with autism spectrum disorder in training social skills. The system is intended to ...

A privacy-first AI can diagnose a life-shortening hormone disorder—just from a photo of your hand.

Between four and 10 million people in the U.S. have fibromyalgia. Many doctors look askance at the disorder, leading some patients to seek pain relief from substance use.

Leerink Partners Global Healthcare Conference March 8 - 11, 2026 in Miami, FL Fireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view ...

The family and friends of the teen whose body was found behind a South Wilkes-Barre garage last month have started a petition seeking to “turn tragedy into protection” by creating a ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...